In this week's episode, we talk about Sjögren's disease, a relatively common autoimmune disease. We explore the risks of contracting the disease, who gets it, symptoms, and complications. We also explore how the disease works on a mechanical level inside the body by hijacking the immune system, and finish by looking at what treatment looks like today and what's coming down the clinical trial pipeline tomorrow.

References:

• Patel R, Shahane A. The epidemiology of Sjögren’s syndrome. Clinical epidemiology. 2014 Jul 30:247-55. https://doi.org/10.2147/clep.s47399
• Mariette X, Criswell LA. Primary Sjögren’s syndrome. New England Journal of Medicine. 2018 Mar 8;378(10):931-9. https://doi.org/10.1056/NEJMcp1702514
• Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T. The diagnosis and treatment of Sjögren’s syndrome. Deutsches Ärzteblatt International. 2017 May 26;114(20):354.https://doi.org/10.3238/arztebl.2017.0354
• Baldini C, Fulvio G, La Rocca G, Ferro F. Update on the pathophysiology and treatment of primary Sjögren syndrome. Nature Reviews Rheumatology. 2024 Aug;20(8):473-91. https://doi.org/10.1038/s41584-024-01135-3
• Yang Y, Shen Z, Shi F, Wang F, Wen N. Efgartigimod as a novel FcRn inhibitor for autoimmune disease. Neurological Sciences. 2024 Sep;45(9):4229-41. https://link.springer.com/article/10.1007/s10072-024-07460-5

Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released.

Follow us on Social Media:
Facebook
Instagram
Twitter
LinkedIn
Tiktok
Youtube

For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! Podcast and MedEvidence.com

Thank you for listening!